Table 1.
Somatic mutations in epigenetic processes identified in patients with MDS
OS indicates overall survival; HSC, hematopoietic self-renewal, and RS, ringed sideroblasts.
*Mutations in multiple additional members of the spliceosome have been identified in < 5% of MDS patients, including SF3A1, PRPF40B, U2AF65, and SF1. The biologic and clinical associations of these additional alterations are not well understood currently.
